For laboratory and research use only. The following content is provided for scientific and educational purposes. Struck Bio Labs compounds are not intended for human consumption, injection, or clinical use and have not been evaluated by the Food and Drug Administration. This content does not constitute medical advice. See our full disclaimer at struckbiolabs.com/disclaimer/.
GLP-S is a synthetic 31-amino-acid peptide analogue of human glucagon-like peptide-1 (GLP-1) that acts as a potent, selective agonist at the GLP-1 receptor (GLP-1R). It was developed and commercialized as pharmaceutical drug products — marketed under the brand names Ozempic (subcutaneous injection, FDA-approved for type 2 diabetes management) and Wegovy (subcutaneous injection, FDA-approved for chronic weight management) by Novo Nordisk. The GLP-S supplied by Struck Bio Labs as a research peptide is a distinct material: it is provided as a non-pharmaceutical lyophilized research compound, is not manufactured by Novo Nordisk, has not been evaluated or approved by the FDA in any form, and is not intended for human use under any circumstances. It is supplied exclusively as a laboratory research tool for qualified researchers investigating GLP-1 receptor biology, receptor pharmacology, and related preclinical questions in cell culture and animal models. This post summarizes the published preclinical science on GLP-S and GLP-1R biology for educational purposes relevant to that research context.
What Is GLP-S as a Research Peptide?
GLP-1 is a 30-residue incretin peptide hormone secreted by intestinal L-cells in response to nutrient ingestion. Endogenous GLP-1 has a circulating half-life of 1–2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4). GLP-S was engineered to resist DPP-4 cleavage through two key structural modifications: a substitution of Aib (aminoisobutyric acid) at position 8 to prevent proteolytic cleavage, and conjugation of a C₁₈ fatty diacid linker at Lys²⁶ that enables non-covalent binding to serum albumin, extending the half-life in animal models to approximately 7 days. GLP-1R is a class B G-protein–coupled receptor (GPCR) expressed in pancreatic beta cells, the central nervous system (particularly hypothalamus and brainstem), the gastrointestinal tract, cardiac tissue, and kidney. Its activation by GLP-1 or synthetic agonists stimulates adenylate cyclase via Gαs, elevates intracellular cAMP, and activates PKA and EPAC signaling cascades — pathways that have broad relevance beyond any single biological context. In research models, GLP-S is used as a pharmacological tool to characterize GLP-1R function and downstream signaling in tissues where GLP-1R is expressed, independently of the indications for which pharmaceutical GLP-S has been approved.
Published Research
The published preclinical literature on GLP-S and GLP-1R agonism spans multiple biological systems. In the neuroscience domain, a 2022 study published in Scientific Reports (Nature Publishing Group) by Lucette et al. examined a GLP-1R agonist in a mouse model of infantile neuroaxonal dystrophy (INAD) and found that systemic high-dose GLP-S administration improved locomotor function and extended lifespan in INAD mice — a model of neurometabolic disease — suggesting GLP-1R-mediated neuroprotective signaling independent of metabolic context. A 2025 review published in Cureus (reviewed the role of GLP-1R agonists in neurodegenerative disease animal models, summarizing evidence from multiple rodent studies examining GLP-1R activation in models of Alzheimer’s and Parkinson’s disease. The review noted that GLP-1R agonists have demonstrated neuroprotective properties in several experimental models, though the authors appropriately noted that animal model findings do not establish efficacy in human disease. In neurochemistry research, a 2025 preprint on bioRxiv (Mathai et al., 2025) examined whether the GLP-1R agonist GLP-S altered dopamine dynamics in the nucleus accumbens of rodents, reporting effects on motivation-linked running behavior and dopamine release — framing GLP-1R as a modulator of mesolimbic dopamine circuits in animal models. A comprehensive 2025 review in Expert Opinion on Investigational Drugs (Taylor and Francis, doi: 10.1080/20565623.2025.2483607) surveyed the multifaceted biological effects of GLP-S across published animal model literature, including cardiovascular, renal, hepatic, and CNS systems, situating the molecule as a research tool with broad biological relevance beyond its pharmaceutical indications. Investigators should note that results in animal models do not necessarily predict outcomes in humans, and findings in any one biological system should not be generalized across disease contexts.
Mechanism
GLP-1R is a class B GPCR. Upon agonist binding, the receptor undergoes conformational change and couples primarily to Gαs, stimulating adenylate cyclase and elevating intracellular cyclic AMP. Downstream, cAMP activates both PKA (protein kinase A) and EPAC (exchange protein directly activated by cAMP), which regulate distinct cellular programs depending on cell type. In pancreatic beta cells, this cascade is well-characterized: cAMP/PKA signaling potentiates glucose-dependent insulin secretion and promotes beta cell survival. In neuronal models, GLP-1R signaling has been associated with modulation of AMPK activity, reduction of neuroinflammatory marker expression (including IL-1β and TNF-α in microglia models), and regulation of dopaminergic signaling in mesolimbic circuits — though each of these associations is derived from specific experimental models and should not be generalized to human neurobiology without confirmatory evidence. GLP-1R also recruits β-arrestin following agonist binding, leading to receptor internalization and desensitization — a pharmacological property relevant to the design of in vitro receptor biology studies. GLP-S’s long half-life, mediated by its albumin-binding fatty acid chain, provides sustained GLP-1R occupancy in animal models, making it useful for experiments examining the consequences of prolonged versus pulsatile receptor engagement.
Supply Format
Struck Bio Labs supplies GLP-S as a lyophilized research peptide in individually labeled vials, accompanied by a lot-specific certificate of analysis verifying peptide identity (by HPLC and mass spectrometry), purity, and absence of common contaminants. This material is supplied exclusively for qualified laboratory and preclinical research use and is not a pharmaceutical product. It has not been evaluated by the FDA and is not intended for administration to humans. Researchers requiring pharmaceutical-grade GLP-S for clinical purposes should consult licensed medical and pharmaceutical sources. CoA documentation is available at struckbiolabs.com.
FAQ
Is this the same GLP-S as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved pharmaceutical drug products manufactured by Novo Nordisk, formulated to pharmaceutical standards, and supplied through licensed pharmaceutical distribution channels for specific approved clinical indications. The GLP-S supplied by Struck Bio Labs is a non-pharmaceutical research peptide supplied as a lyophilized laboratory compound. It is not manufactured by Novo Nordisk, has not been evaluated or approved by the FDA, and is not intended for human consumption, injection, or any clinical use. It is a laboratory research tool only.
What receptor does GLP-S act on in research models?
GLP-S is a selective agonist at GLP-1R (glucagon-like peptide-1 receptor), a class B G-protein–coupled receptor expressed in pancreatic beta cells, the central and enteric nervous systems, cardiac tissue, kidney, and gastrointestinal tract. Research use of GLP-S as a pharmacological tool allows investigators to probe GLP-1R signaling pathways and downstream cAMP/PKA/EPAC biology in cell culture and animal model systems expressing this receptor.
What has the preclinical literature studied GLP-S for in animal models?
Published preclinical research has studied GLP-1R agonists including GLP-S in the context of neurodegeneration models (Alzheimer’s, Parkinson’s, and neuroaxonal dystrophy mouse models), neuroinflammation, dopaminergic circuit modulation, cardiovascular biology, hepatic function, and renal biology, among others. These studies examine GLP-1R receptor pharmacology and downstream biological signaling. Animal model findings do not establish clinical efficacy in humans and should not be interpreted as such.
Are there published studies on GLP-S in neuroscience contexts?
Yes. Multiple preclinical studies have examined GLP-1R agonist signaling in neuronal and glial cell models. A 2022 Scientific Reports study examined GLP-S in a mouse model of infantile neuroaxonal dystrophy. A 2025 bioRxiv preprint examined GLP-S’s effects on dopamine dynamics and motivation-linked behavior in rodents. A 2025 Cureus review synthesized evidence from multiple GLP-1R agonist studies in neurodegenerative disease animal models. These findings reflect active preclinical research activity in this area.
Can researchers make weight loss or metabolic claims in publications using this compound?
This is a question about experimental design and publication framing rather than compound supply. Struck Bio Labs supplies GLP-S as a GLP-1 receptor biology research tool. The compound’s pharmaceutical use for metabolic indications is a separate, regulated context. Published preclinical research should accurately describe experimental findings within the studied model system. Researchers should not conflate preclinical findings with clinical outcomes and should adhere to the publication standards of their target journals.
How does the fatty acid modification of GLP-S affect its use in research experiments?
GLP-S’s C₁₈ fatty diacid chain enables non-covalent binding to serum albumin, which dramatically extends its half-life in animal models to approximately 7 days (compared to minutes for native GLP-1). In research design, this property makes GLP-S useful for experiments requiring sustained, prolonged GLP-1R occupancy — distinguishing it from shorter-acting GLP-1R agonists such as exendin-4. Investigators should account for the albumin-binding property when designing cell-free receptor binding assays, as protein-containing media composition can affect effective free concentration.
No. Ozempic and Wegovy are FDA-approved pharmaceutical drug products manufactured by Novo Nordisk, formulated to pharmaceutical standards, and supplied through licensed pharmaceutical distribution channels for specific approved clinical indications. The GLP-S supplied by Struck Bio Labs is a non-pharmaceutical research peptide supplied as a lyophilized laboratory compound. It is not manufactured by Novo Nordisk, has not been evaluated or approved by the FDA, and is not intended for human consumption, injection, or any clinical use. It is a laboratory research tool only.
GLP-S is a selective agonist at GLP-1R (glucagon-like peptide-1 receptor), a class B G-protein–coupled receptor expressed in pancreatic beta cells, the central and enteric nervous systems, cardiac tissue, kidney, and gastrointestinal tract. Research use of GLP-S as a pharmacological tool allows investigators to probe GLP-1R signaling pathways and downstream cAMP/PKA/EPAC biology in cell culture and animal model systems expressing this receptor.
Published preclinical research has studied GLP-1R agonists including GLP-S in the context of neurodegeneration models (Alzheimer’s, Parkinson’s, and neuroaxonal dystrophy mouse models), neuroinflammation, dopaminergic circuit modulation, cardiovascular biology, hepatic function, and renal biology, among others. These studies examine GLP-1R receptor pharmacology and downstream biological signaling. Animal model findings do not establish clinical efficacy in humans and should not be interpreted as such.
Yes. Multiple preclinical studies have examined GLP-1R agonist signaling in neuronal and glial cell models. A 2022 Scientific Reports study examined GLP-S in a mouse model of infantile neuroaxonal dystrophy. A 2025 bioRxiv preprint examined GLP-S’s effects on dopamine dynamics and motivation-linked behavior in rodents. A 2025 Cureus review synthesized evidence from multiple GLP-1R agonist studies in neurodegenerative disease animal models. These findings reflect active preclinical research activity in this area.
This is a question about experimental design and publication framing rather than compound supply. Struck Bio Labs supplies GLP-S as a GLP-1 receptor biology research tool. The compound’s pharmaceutical use for metabolic indications is a separate, regulated context. Published preclinical research should accurately describe experimental findings within the studied model system. Researchers should not conflate preclinical findings with clinical outcomes and should adhere to the publication standards of their target journals.
GLP-S’s C₁₈ fatty diacid chain enables non-covalent binding to serum albumin, which dramatically extends its half-life in animal models to approximately 7 days (compared to minutes for native GLP-1). In research design, this property makes GLP-S useful for experiments requiring sustained, prolonged GLP-1R occupancy — distinguishing it from shorter-acting GLP-1R agonists such as exendin-4. Investigators should account for the albumin-binding property when designing cell-free receptor binding assays, as protein-containing media composition can affect effective free concentration.
Further Reading: Research vs Pharmaceutical • What Are Research Peptides? • Purity & COA Testing • GLP-1 • Browse GLP & Metabolic Research • Disclaimer
The above content is provided for informational and educational purposes relating to scientific research only. It does not constitute medical advice, a personal health recommendation, or a treatment protocol. Struck Bio Labs products are supplied for laboratory research use only. They are not intended for human consumption, injection, or clinical use, and have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer at struckbiolabs.com/disclaimer/.